SC Pharmaceuticals(SZ:002693) news flash·2025-07-14 12:31Core Viewpoint - *ST Shuangcheng (002693.SZ) expects a net loss of 13 million to 19 million yuan for the first half of 2025, compared to a loss of 16.9462 million yuan in the same period last year [1] Company Summary - The company attributes the expected loss to significant changes in market supply and pricing due to ongoing reforms in the pharmaceutical industry, with a notable decline in sales volume for non-winning bid products and a substantial drop in prices for winning bid products [1] - The company's main product, Thymosin Alpha 1 injection, experienced a price reduction during the new bidding period, leading to decreased domestic sales profits [1] - However, the company achieved a milestone with the approval of the abbreviated new drug application (ANDA) for Paclitaxel Injection (albumin-bound) by the U.S. Food and Drug Administration (FDA) in May 2025, which has begun to generate export sales [1] - Additionally, there was an increase in export revenue from the injection of Bivalirudin, contributing to improved export profits [1] - Overall, these factors resulted in minimal changes to the company's overall performance [1]